Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure
Journal of Viral Hepatitis · 2025
DOI: 10.1111/jvh.70079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Amir M Mohareb und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic, Withholding Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Discontinuing antivirals in chronic hepatitis B virus (HBV) ‘e’ antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare. We simulated the probability of virologic relapse as an exponential decay function from the time of antiviral cessation. We used literature‐based estimates for input probabilities following virologic relapse: clinical relapse (60%, conditional on virologic relapse), hepatitis flare (57%, conditional on clinical relapse) and HBsAg‐loss (6%–8%). We projected HBsAg loss, cirrhosis, HCC, and survival. In 10 years, cessation strategies would increase cumulative incidence of HBsAg loss from 4.6% to 12.9%–17.3% but would not appreciably change survival (from 90.6% with continuation to 88.1%–89.0%). In an undifferentiated population, continuation would be a preferred strategy to increase average life expectancy (by 0.75–1.05 years) unless HBsAg loss following treatment cessation was > 46%. Sensitivity analyses showed that the decision to continue or stop antivirals would depend on the off‐treatment rates of cirrhosis and HCC for people who remain HBsAg‐positive but do not fulfil retreatment criteria. Careful selection of people for antiviral cessation using quantitative HBsAg levels could improve survival compared with continuation. Clinical practice guidelines should emphasise selective application of antiviral cessation to persons most likely to lose HBsAg without experiencing liver‐related complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Public Health Service of Amsterdam, Amsterdam, the Netherlands.
ORCID-Profile: Amir M Mohareb, Anders Boyd, Emily P Hyle
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Mohareb, A. M., Ezaz, G., Kim, A. Y., Freedberg, K. A., Boyd, A., & Hyle, E. P. (2025). Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70079
Vancouver
Mohareb AM, Ezaz G, Kim AY, Freedberg KA, Boyd A, Hyle EP. Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.70079
BibTeX
@article{Mohareb2025,
author = {Mohareb, Amir M and Ezaz, Ghideon and Kim, Arthur Y and Freedberg, Kenneth A and Boyd, Anders and Hyle, Emily P},
title = {Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure},
journal = {Journal of Viral Hepatitis},
year = {2025},
doi = {10.1111/jvh.70079}
}
EUVIMED